BDR Pharmaceuticals is acquiring a controlling stake in the oral solid formulations business of Acme Formulation and its subsidiaries from existing shareholders led by private equity investor PAG. Announced on November 9, 2026, the transaction will expand BDR’s contract development and manufacturing organisation (CDMO) capabilities, adding specialised manufacturing expertise in thyroid therapies, female sex hormones and general pharmaceutical products. The financial terms have not been disclosed.
The transaction also separates two important parts of the Acme business. BDR will take control of the oral formulations operations, while PAG and Acme founder Viral Shah will retain full ownership of Immacule Lifesciences, the group’s sterile injectables contract manufacturing business. BDR also plans to use Acme’s USFDA-approved manufacturing infrastructure alongside its recently acquired US generic-drug application portfolio, potentially strengthening its position in the American pharmaceutical market.
Key Takeaways
- BDR Pharmaceuticals will acquire a controlling stake in Acme Formulation’s oral solid formulations business.
- Existing shareholders led by private equity firm PAG are selling the controlling stake.
- The financial terms of the announced transaction have not been disclosed.
- The acquisition adds capabilities in thyroid medicines, female sex hormones and general pharmaceutical products.
- BDR plans to use Acme’s USFDA-approved manufacturing facilities to support its US generics business.
- PAG and Acme founder Viral Shah will retain full ownership of Immacule Lifesciences, the sterile injectables business.
- PAG acquired control of Acme in 2021 for approximately ₹1,054 crore, or $145 million.
- The transaction strengthens BDR’s strategy of expanding its pharmaceutical manufacturing and international business.
What Is the BDR Pharma-Acme Deal?
The transaction involves BDR Pharmaceuticals acquiring a controlling stake in the oral solid formulations business of Acme Formulation Private Limited and its subsidiaries.
Acme operates in the contract development and manufacturing organisation segment, commonly known as CDMO.
A CDMO develops and manufactures pharmaceutical products for other drug companies. Instead of building manufacturing facilities and handling every stage of production themselves, pharmaceutical companies can outsource product development, formulation and manufacturing to specialised partners.
Acme has capabilities in complex oral formulations, including tablets and capsules, as well as specialised therapeutic products.
The acquisition will give BDR access to manufacturing capabilities that complement its existing pharmaceutical operations.
The companies have not disclosed the transaction’s financial value, the precise ownership percentage being transferred or the expected completion timeline.
O3 Capital acted as BDR Pharma’s exclusive financial advisor.
Why Is BDR Pharmaceuticals Acquiring Acme’s Oral Formulations Business?
The acquisition is part of BDR Pharma’s strategy to expand its CDMO platform and strengthen its international presence.
The company already operates across specialised pharmaceutical segments, including oncology and critical care. Acme adds capabilities in areas such as thyroid therapies, female sex hormones and general pharmaceutical products.
This gives BDR a broader manufacturing and product-development platform.
1. Expansion into Thyroid and Hormonal Medicines
Acme’s capabilities in thyroid products and female sex hormone formulations are important additions to BDR’s existing portfolio.
These are specialised pharmaceutical categories requiring manufacturing expertise and consistent product quality.
The acquisition could help BDR expand its range of products and offer additional manufacturing services to domestic and international pharmaceutical companies.
2. Strengthening Its CDMO Platform
The CDMO business model allows pharmaceutical companies to generate revenue by developing and manufacturing medicines for other companies.
For BDR, acquiring an established manufacturing platform could help expand its customer relationships, product capabilities and manufacturing capacity.
It also offers an opportunity to build a more integrated pharmaceutical business covering product development, manufacturing and commercialisation.
3. Expanding International Markets
Acme has an established export presence, supplying pharmaceutical products to more than 40 countries, according to industry reports.
Its manufacturing infrastructure and existing capabilities could help BDR expand its international operations.
The United States is particularly important because BDR intends to use Acme’s manufacturing base alongside its recently acquired portfolio of generic-drug applications.
How Acme’s Manufacturing Facilities Could Help BDR Enter the US Market
One of the most important strategic benefits of the transaction is access to Acme’s USFDA-approved manufacturing infrastructure.
The US pharmaceutical market is one of the world’s largest and most competitive markets for generic medicines.
Companies seeking to sell generic drugs in the United States must meet regulatory requirements established by the US Food and Drug Administration.
A key part of this process involves an Abbreviated New Drug Application, or ANDA.
An ANDA is a regulatory application submitted to the USFDA for approval to market a generic version of an existing approved medicine.
BDR has recently acquired a portfolio of ANDAs and sees an opportunity to combine those product approvals and applications with Acme’s manufacturing capabilities.
This could help the company gradually move towards commercialising more of its own generic products in the US market.
Why the combination matters
| BDR’s existing capabilities | Acme’s additional capabilities |
|---|---|
| Specialised pharmaceutical products | Oral solid formulations |
| Oncology and critical care focus | Thyroid therapies |
| Recently acquired US ANDA portfolio | Female sex hormone products |
| Expanding CDMO operations | USFDA-approved manufacturing base |
| International pharmaceutical business | Established export presence |
The combination could strengthen BDR’s position across more stages of the pharmaceutical value chain.
However, access to an approved manufacturing facility does not automatically mean every product can be manufactured and sold in the US. Product-specific regulatory requirements, facility compliance, customer contracts and commercial execution will remain important.
PAG’s Exit from the Oral Formulations Business
The transaction also marks an important development for private equity investor PAG.
PAG acquired a controlling stake in Acme Formulation in 2021 through its PAG Asia III buyout fund.
The acquisition was valued at approximately $145 million, equivalent to around ₹1,054 crore at the time.
Acme founder Viral Shah retained a significant minority interest following the investment and continued to play an important role in the business.
According to earlier reporting by The Economic Times, PAG owned approximately 62% of Acme, while Shah held around 31%, with the remaining stake belonging to other investors.
The newly announced transaction allows PAG to transfer control of the oral solid formulations business to BDR.
However, PAG is not exiting the entire Acme-related business.
It will retain full ownership of Immacule Lifesciences alongside Viral Shah, shifting its focus towards expanding the sterile injectables platform.
What happened to the original Acme business?
| Business | Ownership direction after the transaction |
|---|---|
| Oral solid formulations business | Controlling stake to be acquired by BDR Pharma |
| Immacule Lifesciences | Retained by PAG and Viral Shah |
| Sterile injectables operations | Remain under Immacule |
The separation allows the two sides to pursue different growth strategies.
BDR can concentrate on expanding oral formulations and its CDMO platform, while PAG and Shah can focus on developing Immacule’s sterile injectables operations.
Why PAG Is Retaining Immacule Lifesciences
Immacule Lifesciences is focused on contract manufacturing of sterile injectable medicines.
These products include liquid and lyophilised vials, pre-filled syringes and cartridges.
Sterile injectable manufacturing requires specialised infrastructure and stringent quality-control processes because the products must meet strict sterility and safety standards.
Immacule operates two manufacturing facilities in Nalagarh, Himachal Pradesh.
According to the companies’ statements, the facilities represent a combined investment of approximately $100 million and employ around 750 people.
Its recently commissioned facility has expanded its manufacturing capabilities, with annual capacity exceeding 200 million units.
The company serves pharmaceutical customers across India and international markets, with capabilities spanning oncology, ophthalmology and general injectables.
PAG sees an opportunity to develop Immacule into a larger global sterile injectables platform.
For the private equity investor, retaining Immacule provides a separate business with its own manufacturing capabilities, customer relationships and international growth opportunities.
What Is the Reported Valuation of Acme?
Although the companies have not disclosed the financial terms of the transaction, earlier reporting provides some context.
In July 2026, The Economic Times reported that discussions around a possible acquisition of Acme could value the business at approximately $200 million to $250 million, citing people familiar with the matter.
That report referred to the broader proposed transaction discussions at the time.
It should not be treated as the confirmed purchase price of the oral solid formulations business announced in November.
The actual consideration, ownership percentage and financial structure of the completed transaction remain undisclosed.
For investors and the pharmaceutical industry, these details will be important in assessing the economics of the acquisition.
What Does the Acquisition Mean for BDR Pharma’s Growth Strategy?
The acquisition fits into BDR Pharma’s wider expansion plans.
The company has been building its presence in specialised medicines and manufacturing capabilities through strategic investments.
BDR is backed by Multiples Private Equity, which led an investment of approximately ₹685 crore, or $91 million, for a stake of nearly 10% in the company in 2022.
The Economic Times has also reported that BDR was targeting an initial public offering by 2027 and planned to invest approximately ₹700 crore over the following years in organic and inorganic expansion.
The Acme acquisition could support this strategy by expanding its manufacturing capabilities and international reach.
Potential benefits for BDR
- A broader portfolio of pharmaceutical formulations.
- Additional manufacturing capabilities in specialised therapies.
- Greater access to international customers.
- An established manufacturing base for its US generics ambitions.
- Opportunities to expand CDMO services.
- Potential for greater integration between product development and commercial manufacturing.
However, acquisitions also bring execution risks.
BDR will need to manage the integration of the acquired operations, maintain existing customer relationships and ensure manufacturing facilities continue meeting regulatory standards.
The company will also need to demonstrate that the additional capabilities can translate into sustainable revenue and profitability.
What This Deal Signals for India’s Pharmaceutical CDMO Industry
The transaction reflects the continuing importance of manufacturing capabilities in India’s pharmaceutical industry.
Indian drugmakers are increasingly looking beyond the traditional business of selling medicines under their own brands.
CDMO operations offer another growth opportunity because pharmaceutical companies across the world require specialised partners for research, development and manufacturing.
Several factors are supporting this business model:
Global outsourcing: Pharmaceutical companies can use external manufacturing partners to manage costs and access specialised production capabilities.
Regulatory expertise: Facilities with approvals from major international regulators can serve customers in more demanding markets.
Specialised formulations: Hormones, complex oral medicines and sterile injectables require capabilities that may not be available at every manufacturing facility.
International expansion: Indian CDMOs can use their manufacturing infrastructure and technical expertise to serve customers across multiple countries.
BDR’s acquisition demonstrates how Indian pharmaceutical companies can use acquisitions to expand into complementary manufacturing categories rather than relying entirely on organic growth.
The deal also shows how private equity investors can restructure pharmaceutical platforms by separating businesses with different strategic priorities.
The Bigger Picture
BDR Pharma’s acquisition of Acme’s oral formulations business is more than an expansion of manufacturing capacity. It gives BDR access to specialised pharmaceutical capabilities, established export operations and infrastructure that could support its ambitions in the US generics market. At the same time, the transaction allows PAG and Acme founder Viral Shah to concentrate on building Immacule into a larger sterile injectables business.
The long-term success of the transaction will depend on how effectively BDR integrates the acquired operations and converts the additional capabilities into commercial growth. The undisclosed financial terms also mean that investors cannot yet fully assess the acquisition’s valuation or expected returns. Nevertheless, the deal highlights the growing importance of strategic acquisitions in India’s pharmaceutical CDMO sector as companies seek scale, specialised manufacturing expertise and stronger international positions.
Frequently Asked Questions
1. What is BDR Pharma acquiring from Acme?
BDR Pharmaceuticals is acquiring a controlling stake in the oral solid formulations business of Acme Formulation and its subsidiaries from existing shareholders led by PAG.
2. Has the BDR Pharma-Acme deal value been disclosed?
No. The companies have not disclosed the financial terms of the transaction. Earlier reports discussed a possible valuation of $200 million to $250 million during negotiations, but this is not a confirmed transaction value.
3. Why is BDR Pharma acquiring Acme’s business?
The acquisition will strengthen BDR’s CDMO platform and add manufacturing capabilities in thyroid therapies, female sex hormones and general pharmaceutical products.
4. What happens to Immacule Lifesciences after the deal?
PAG and Acme founder Viral Shah will retain full ownership of Immacule Lifesciences, the group’s sterile injectable-focused contract manufacturing business.
5. How will the acquisition help BDR Pharma in the US?
BDR plans to use Acme’s USFDA-approved manufacturing infrastructure alongside its recently acquired portfolio of ANDAs to support the commercialisation of generic medicines in the United States.
6. How much did PAG pay to acquire Acme in 2021?
PAG acquired a controlling stake in Acme in 2021 for approximately $145 million, equivalent to around ₹1,054 crore.
7. What is a CDMO in the pharmaceutical industry?
A contract development and manufacturing organisation develops and manufactures medicines for other pharmaceutical companies. It allows drugmakers to outsource product development and manufacturing to specialised partners.
8. What is an ANDA?
An Abbreviated New Drug Application is a regulatory submission to the USFDA seeking approval to market a generic version of an already approved medicine in the United States.
Looking Ahead
BDR Pharma’s acquisition of Acme’s oral formulations business strengthens its position in India’s pharmaceutical manufacturing sector and supports its ambition to expand internationally. The addition of specialised formulations, manufacturing infrastructure and export capabilities could create new opportunities across its CDMO and generic-drug businesses. Its plans to combine Acme’s facilities with its US ANDA portfolio will be particularly important to watch.
For PAG, the transaction creates an opportunity to focus on Immacule and its sterile injectables business rather than maintaining exposure to both manufacturing segments. The next milestones will include completion of the transaction, integration of the oral formulations operations and progress in commercialising products for international markets. The acquisition’s financial impact will become clearer once the companies disclose more details about the transaction and its contribution to BDR’s business.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
